Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,808
datasets available to search
ShareScore release 0.9.0
Dataset results
1,808 results for “dendritic cells”
Increased sCD163 and sCD14 plasmatic levels and depletion of peripheral blood pro-inflammatory monocytes, myeloid and plasmacytoid dendritic cells in patients with severe COVID-19 pneumonia
<p><strong>Background: </strong>Emerging evidence argues that monocytes, circulating innate immune cells, are principal players in COVID-19 pneumonia. The study aimed to investigate the role of soluble (s)CD163 and sCD14 plasmatic levels in predicting disease severity and characterize peripheral blood monocytes and dendritic cells (DCs), in patients with COVID-19 pneumonia (COVID-19 subjects). </p> <p><strong>Methods:</strong> On admission, in COVID-19 subjects sCD163 and sCD14 plasmatic levels, and peripheral blood monocyte and DC subsets were compared to healthy donors (HDs). According to clinical outcome, COVID-19 subjects were divided into ARDS and non-ARDS groups. </p> <p><strong>Results:</strong> Compared to HDs, COVID-19 subjects showed higher sCD163 (p<0.0001) and sCD14 (p<0.0001) plasmatic levels. We observed higher sCD163 plasmatic levels in the ARDS group compared to the non-ARDS one (p=0.002). The cut-off for sCD163 plasmatic level greater than 2032 ng/ml was predictive of disease severity (AUC: 0.6786, p=0.0022; sensitivity 56.7% [CI: 44.1-68.4] specificity 73.8% [CI: 58.9-84.7]). Positive correlation between plasmatic levels of sCD163, LDH and IL-6 and between plasmatic levels of sCD14, D-dimer and ferritin were found. Compared to HDs, COVID-19 subjects showed lower percentages of non-classical (p=0.0012) and intermediate monocytes (p=0.0447), slanDCs (p<0.0001), myeloid DCs (mDCs, p<0.0001) and plasmacytoid DCs (pDCs, p=0.0014). Compared to the non-ARDS group, the ARDS group showed lower percentages of non-classical monocytes (p=0.0006), mDCs (p=0.0346) and pDCs (p=0.0492). </p> <p><strong>Conclusions:</strong> The increase in sCD163 and sCD14 plasmatic levels, observed on hospital admission in COVID-19 subjects, especially in those who developed ARDS, and the correlations of these monocyte/macrophage activation markers with typical inflammatory markers of COVID-19 pneumonia, underline their potential use to assess the risk of progression of the disease. In an early stage of the disease, the assessment of sCD163 plasmatic levels could have clinical utility in predicting the severity of COVID-19 pneumonia. </p>
Data from: In vivo tracking of dendritic cell using MRI reporter gene, ferritin
The noninvasive imaging of dendritic cells (DCs) migrated into lymph nodes (LNs) can provide helpful information on designing DCs-based immunotherapeutic strategies. This study is to investigate the influence of transduction of human ferritin heavy chain (FTH) and green fluorescence protein (GFP) genes on inherent properties of DCs, and the feasibility of FTH as a magnetic resonance imaging (MRI) reporter gene to track DCs migration into LNs. FTH-DCs were established by the introduction of FTH and GFP genes into the DC cell line (DC2.4) using lentivirus. The changes in the rate of MRI signal decay (R2*) resulting from FTH transduction were analyzed in cell phantoms as well as popliteal LN of mice after subcutaneous injection of those cells into hind limb foot pad by using a multiple gradient echo sequence on a 9.4 T MR scanner. The transduction of FTH and GFP did not influence the proliferation and migration abilities of DCs. The expression of co-stimulatory molecules (CD40, CD80 and CD86) in FTH-DCs was similar to that of DCs. FTH-DCs exhibited increased iron storage capacity, and displayed a significantly higher transverse relaxation rate (R2*) as compared to DCs in phantom. LNs with FTH-DCs exhibited negative contrast, leading to a high R2* in both in vivo and ex vivo T2*-weighted images compared to DCs. On histological analysis FTH-DCs migrated to the subcapsular sinus and the T cell zone of LN, where they highly expressed CD25 to bind and stimulate T cells. Our study addresses the feasibility of FTH as an MRI reporter gene to track DCs migration into LNs without alteration of their inherent properties. This study suggests that FTH-based MRI could be a useful technique to longitudinally monitor DCs and evaluate the therapeutic efficacy of DC-based vaccines.
Scripts reproducing the analyses of the paper "HCMV exploits STING signaling and counteracts IFN and ISG induction to facilitate infection of dendritic cells" by Costa et al
<p>This is the code to reproduce the data analyses in the manuscript "HCMV exploits STING signaling and counteracts IFN and ISG induction to facilitate infection of dendritic cells".</p> <p>Required software and packages:</p> <p>R (4.2.1)<br>circlize (0.4.15)<br>ComplexHeatmap (2.12.1)<br>cowplot (1.1.1)<br>future (1.28.0)<br>ggalluvial (0.12.5)<br>ggpubr (0.4.0)<br>ggrepel (0.9.1)<br>GSVA (1.44.5)<br>msigdbr (7.5.1)<br>patchwork (1.1.2)<br>plyr (1.8.7)<br>presto (1.0.0)<br>RColorBrewer (1.1-3)<br>reshape2 (1.4.4)<br>sctransform (0.3.5)<br>Seurat (4.2.0)<br>SeuratDisk (0.0.0.9020)<br>SeuratWrappers (0.3.1)<br>velocyto.R (0.6)</p> <p>Howto: Execute all scripts in order by first changing into the directory, and then executing the script:</p> <pre><code>cd 00_QC; Rscript 00_QC.R; cd ..</code></pre>
Ascorbic acid supports ex vivo generation of plasmacytoid dendritic cells from circulating hematopoietic stem cells: RNA-seq dataset
<p>Plasmacytoid dendritic cells (pDCs) constitute a rare type of immune cell with multifaceted functions, but their potential use as a cell-based immunotherapy is challenged by the scarce cell numbers that can be extracted from blood. Here, we systematically investigate culture parameters for generating pDCs from hematopoietic stem and progenitor cells (HSPCs). Using optimized conditions combined with implementation of HSPC pre-expansion, we generate an average of 465 million HSPC-derived pDCs (HSPC-pDCs) starting from 100,000 cord blood-derived HSPCs. Furthermore, we demonstrate that such protocol allows HSPC-pDC generation from whole blood HSPCs, and these cells display a pDC phenotype and function. Using GMP compliant medium, we observe a remarkable loss of TLR7/9 responses, which is rescued by ascorbic acid supplementation. Ascorbic acid induces transcriptional signatures associated with pDC-specific innate immune pathways suggesting an undescribed role of ascorbic acid for pDC functionality. This constitutes the first protocol for generating pDCs from whole blood, and lay the foundation for investigating HSPC-pDCs for cell-based immunotherapy.</p>
dataset of dendritic cell for vaccine of CBAVD
<p>THIS IS THE DATASET FOR DENDRITIC CEL LAB RESULT TO BE USED FOR cbavd BASE OF VACCINE</p>
CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy
<p>Tumors exploit numerous immune checkpoints including those deployed by myeloid cells to curtail anti-tumor immunity. Here, we show that the C-type lectin receptor CLEC-1 expressed by myeloid cells senses dead cells killed by programmed necrosis. Moreover, we identified TRIM21 as an endogenous ligand over-expressed in various cancers. Interestingly, we observed that in mice CLEC-1 blockade combined with chemotherapy to prolong survival in tumor models. Loss of CLEC-1 reduced the accumulation of immunosuppressive myeloid cells in tumors and invigorated the activation state of dendritic cells (DCs), thereby increasing T cell responses. Mechanistically, we found that the absence of CLEC-1 increased the cross-presentation of dead-cell associated antigens by conventional type-1 DCs. Importantly, we identified anti-human CLEC-1 antagonist antibodies able to enhance anti-tumor immunity in CLEC-1 humanized mice. Altogether, our results demonstrate that CLEC-1 acts as an immune checkpoint in myeloid cells and support CLEC-1 as a novel target for cancer immunotherapy.</p>
Data from: Monocyte recruitment to the dermis and differentiation to dendritic cells increases the targets for Dengue virus replication
Dengue virus (DENV) causes the most prevalent arthropod-borne viral disease in humans. Although Aedes mosquitoes transmit DENV when probing for blood in the skin, no information exists on DENV infection and immune response in the dermis, where the blood vessels are found. DENV suppresses the interferon response, replicates, and causes disease in humans but not wild-type mice. Here, we used mice lacking the interferon-α/β receptor (Ifnar–/–), which had normal cell populations in the skin and were susceptible to intradermal DENV infection, to investigate the dynamics of early DENV infection of immune cells in the skin. CD103+ classical dendritic cells (cDCs), Ly6C– CD11b+ cDCs, and macrophages in the steady-state dermis were initial targets of DENV infection 12-24 hours post-inoculation but then decreased in frequency. We demonstrated recruitment of adoptively-transferred Ly6Chigh monocytes from wild-type and Ifnar–/– origin to the DENV-infected dermis and differentiation to Ly6C+ CD11b+ monocyte-derived DCs (moDCs), which became DENV-infected after 48 hours, and were then the major targets for virus replication. Ly6Chigh monocytes that entered the DENV-infected dermis expressed chemokine receptor CCR2, likely mediating recruitment. Further, we show that ~100-fold more hematopoietic cells in the dermis were DENV-infected compared to Langerhans cells in the epidermis. Overall, these results identify the dermis as the main site of early DENV replication and show that DENV infection in the skin occurs in two waves: initial infection of resident cDCs and macrophages, followed by infection of monocytes and moDCs that are recruited to the dermis. Our study reveals a novel viral strategy of exploiting monocyte recruitment to increase the number of targets for infection at the site of invasion in the skin and highlights the skin as a potential site for therapeutic action or intradermal vaccination.
Dynamic interactome of the MHC I peptide loading complex in human dendritic cells - Source Ib
<p>Source data underlying MS data set (Fig.1). Datafile comprises MaxQuant output files.</p>
MCT1 gene silencing enhances the immune effect of dendritic cells on cervical cancer cells
<p>Statistics for Figure 1-6.</p> <p><strong>Figure S1</strong> Cube maps for the levels of expression for DC markers after sLA exposure and LPS challenge. DCs were first infected with Ad-shCtrl and Ad-shMCT1 adenoviruses for 24 h, then co-cultured with 50 mM sLA or PBS for 48 h, and finally stimulated with 1 ug/mL LPS for 24 h. Flow cytometry was used to detect the expression of CD1a (A), CD80 (B), CD83 (C), CD86 (D) and MHCII (E) in DCs. The column height represents the average value, and the bar of the column is the standard deviation. P value was calculated by Tukey’s honestly significant difference (HSD) test following analysis of variance (ANOVA) testing between multiple groups or by Student's t test between (PBS vs sLA treatment</p> <p>Table S1. Statistics for Figure S1.</p>
MCT1 gene silencing enhances the immune effect of dendritic cells on cervical cancer cells
<p>Figur 1. xlsx, Results of ANOVA as presented in Figure 1.</p> <p>Figur 2. xlsx, Results of ANOVA as presented in Figure 2.</p> <p>Figur 3. xlsx, Results of ANOVA as presented in Figure 3.</p> <p>Figur 4. xlsx, Results of ANOVA as presented in Figure 4.</p> <p>Figur 5. xlsx, Results of ANOVA as presented in Figure 5.</p> <p>Figur 6. xlsx, Results of ANOVA as presented in Figure 6.</p> <p>Figur s1. xlsx, Results of ANOVA as presented in Figure s1.</p> <p>supplementary figure. docx, <strong>Figure S1</strong> Cube maps for the levels of expression for DC markers after sLA exposure and LPS challenge. DCs were first infected with Ad-shCtrl and Ad-shMCT1 adenoviruses for 24 h, then co-cultured with 50 mM sLA or PBS for 48 h, and finally stimulated with 1 ug/mL LPS for 24 h. Flow cytometry was used to detect the expression of CD1a (A), CD80 (B), CD83 (C), CD86 (D) and MHCII (E) in DCs.</p> <p>Table S1. docx, Statistics for Figure S1.</p>
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
ClinicalTrials.gov study NCT01582672. IPD Sharing: NO. Countries: 8. Publications: 1.
Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment
ClinicalTrials.gov study NCT00154713. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma
ClinicalTrials.gov study NCT01974661. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
ClinicalTrials.gov study NCT05325632. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers
ClinicalTrials.gov study NCT00908362. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy
ClinicalTrials.gov study NCT03548571. IPD Sharing: NO. Countries: 1. Publications: 2.
Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy
ClinicalTrials.gov study NCT00700167. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells
ClinicalTrials.gov study NCT00515983. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Engineered Dendritic Cell Vaccines for Multiple Myeloma
ClinicalTrials.gov study NCT06435910. IPD Sharing: NO. Countries: 2. Publications: 2.
Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
ClinicalTrials.gov study NCT03485547. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.